Sintokamide A Is a Novel Antagonist of Androgen Receptor That Uniquely Binds Activation Function-1 in Its Amino-terminal Domain

EPI-001, A Compound Active against Castration-Resistant Prostate Cancer, Targets Transactivation Unit 5 of the Androgen Receptor

(2016) Eva De Mol et al.   ACS Chemical Biology

Targeting Androgen Receptor Activation Function-1 with EPI to Overcome Resistance Mechanisms in Castration-Resistant Prostate Cancer

(2016) Y. C. Yang et al.   CLINICAL CANCER RESEARCH

Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer

(2016) Howard I. Scher et al.   JAMA Oncology

Cotargeting Androgen Receptor Splice Variants and mTOR Signaling Pathway for the Treatment of Castration-Resistant Prostate Cancer

(2015) M. Kato et al.   CLINICAL CANCER RESEARCH

Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy

(2015) Bo Cao et al.   Oncotarget

Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302)

(2014) Dana E. Rathkopf et al.   EUROPEAN UROLOGY

Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer

(2014) Irfan A. Asangani et al.   NATURE

AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer

(2014) Emmanuel S. Antonarakis et al.   NEW ENGLAND JOURNAL OF MEDICINE

Evolution of the Treatment Paradigm for Patients with Metastatic Castration-Resistant Prostate Cancer

(2013) Zafar Malik et al.   ADVANCES IN THERAPY

Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)

(2013) Y. Loriot et al.   ANNALS OF ONCOLOGY

An androgen receptor N-terminal domain antagonist for treating prostate cancer

(2013) Jae-Kyung Myung et al.   JOURNAL OF CLINICAL INVESTIGATION

An F876L Mutation in Androgen Receptor Confers Genetic and Phenotypic Resistance to MDV3100 (Enzalutamide)

(2013) M. Korpal et al.   Cancer Discovery

Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities

(2012) Heather Payne et al.   BJU INTERNATIONAL

ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment

(2012) N. J. Clegg et al.   CANCER RESEARCH

Distinct Transcriptional Programs Mediated by the Ligand-Dependent Full-Length Androgen Receptor and Its Splice Variants in Castration-Resistant Prostate Cancer

(2012) R. Hu et al.   CANCER RESEARCH

Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

(2012) Howard I. Scher et al.   NEW ENGLAND JOURNAL OF MEDICINE

Small Molecule Inhibitors Targeting the “Achilles' Heel” of Androgen Receptor Activity: Figure 1.

(2011) Marianne D. Sadar   CANCER RESEARCH

Resistance to CYP17A1 Inhibition with Abiraterone in Castration-Resistant Prostate Cancer: Induction of Steroidogenesis and Androgen Receptor Splice Variants

(2011) Elahe A. Mostaghel et al.   CLINICAL CANCER RESEARCH

Expression of Androgen Receptor Splice Variants in Prostate Cancer Bone Metastases is Associated with Castration-Resistance and Short Survival

(2011) Emma Hörnberg et al.   PLoS One

Androgen Receptor Variants Occur Frequently in Castration Resistant Prostate Cancer Metastases

(2011) Xiaotun Zhang et al.   PLoS One

Regression of Castrate-Recurrent Prostate Cancer by a Small-Molecule Inhibitor of the Amino-Terminus Domain of the Androgen Receptor

(2010) Raymond J. Andersen et al.   CANCER CELL

Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant

(2010) Shihua Sun et al.   JOURNAL OF CLINICAL INVESTIGATION

A Novel Androgen Receptor Splice Variant Is Up-regulated during Prostate Cancer Progression and Promotes Androgen Depletion-Resistant Growth

(2009) Z. Guo et al.   CANCER RESEARCH

Multiple Independent Binding Sites for Small-Molecule Inhibitors on the Oncoprotein c-Myc

(2009) Dalia I. Hammoudeh et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer

(2009) C. Tran et al.   SCIENCE

Ligand-Independent Androgen Receptor Variants Derived from Splicing of Cryptic Exons Signify Hormone-Refractory Prostate Cancer

(2008) R. Hu et al.   CANCER RESEARCH

Sintokamides A to E, Chlorinated Peptides from the SpongeDysideasp. that Inhibit Transactivation of the N-Terminus of the Androgen Receptor in Prostate Cancer Cells

(2008) Marianne D. Sadar et al.   ORGANIC LETTERS